Uncategorized
Ocata Therapeutics Announces Positive Results Reported in a Late Breaking Abstract at the Annual Meeting of the International Society for Stem Cell Research
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, announced today that data will be presented in a Late Breaking Abstract at the International Society for Stem Cell Research (ISSCR) 13th Annual Meeting being held in Stockholm, Sweden, June 24-27. The presentation will provide a follow-up of four prospective safety trials carried out in the United States and also in South Korea. The result
